
UK - Advent's pharmaceutical portfolio company obtains new distribution rights
Speciality European Pharma Ltd (SEP), an Advent Venture Partners portfolio company has obtained distribution rights to Amphocil® for Germany, France and Italy. Amphocil® is a product owned by Three Rivers Pharmaceutical LLC and is presently marketed in a number of countries, including the USA, UK, Sweden, Austria and Portugal. Amphocil® is already approved in Italy and registrations for Germany and France will be initiated later this year. The product is used to treat severe fungal infections which occur primarily in patients with suppressed or compromised immune systems due to disease or medication.
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater